Key result
Concomitant tricuspid annuloplasty during mitral valve surgery for patients with moderate tricuspid regurgitation and significant annular dilatation remains a subject of current controversy.
Why the study?
Does concomitant tricuspid annuloplasty improve outcomes in patients with moderate TR and significant annular dilatation undergoing mitral valve surgery?
Does concomitant tricuspid annuloplasty improve outcomes in patients with moderate TR and significant annular dilatation undergoing mitral valve surgery?
Answers are grounded in this paper and cite their sources.
This text highlights the current controversy and guideline recommendations regarding concomitant tricuspid annuloplasty during mitral valve surgery for patients with moderate TR and annular dilatation.
Tricuspid annuloplasty for moderate to severe TR (Class I, IIb) is the current standard of practice to restore the normal tricuspid annular dimension and function (1,2). The current controversy in atrioventricular surgery concerns the indication for concomitant TA in patients with moderate TR and significant annular dilatation of at least > 40 mm or at least 21 mm/m 2 indexed for body surface area (Class IIb) during mitral valve surgery proposed by the American Heart Association/American College of Cardiology and European Society of Cardiology (1,2,3)
No takes yet. Share an insight, caveat, or question.
Yankah et al. (2022) conducted an editorial in Tricuspid regurgitation. Tricuspid annuloplasty was evaluated. Concomitant tricuspid annuloplasty during mitral valve surgery for patients with moderate tricuspid regurgitation and significant annular dilatation remains a subject of current controversy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: